High expression of IGFBP7 was found to be associated with poor survival and predicted primary therapy resistance in T-ALL patients, while treatment of leukemic cells lines with recombinant protein reduced proliferation [15]. The gene discussed is IGFBP7; the disease is acute lymphoblastic leukemia.